Saturable elimination of piperacillin in critically ill patients: implications for continuous infusion

被引:15
|
作者
Dhaese, S. A. M. [1 ]
Colin, P. [2 ,3 ]
Willems, H. [1 ]
Heffernan, A. [4 ,5 ,6 ]
Gadeyne, B. [1 ]
Van Vooren, S. [7 ]
Depuydt, P. [1 ]
Hoste, E. [1 ]
Stove, V [7 ,8 ]
Verstraete, A. G. [7 ,8 ]
Lipman, J. [4 ,9 ,10 ]
Roberts, J. A. [4 ,6 ,9 ,11 ]
De Waele, J. J. [1 ]
机构
[1] Ghent Univ Hosp, Dept Crit Care Med, C Heymanslaan 10, B-9000 Ghent, Belgium
[2] Univ Groningen, Univ Med Ctr Groningen, Dept Anesthesiol, Groningen, Netherlands
[3] Univ Ghent, Lab Med Biochem & Clin Anal, Ghent, Belgium
[4] Univ Queensland, Univ Queensland Ctr Clin Res, Fac Med, Brisbane, Qld, Australia
[5] Griffith Univ, Sch Med, Southport, Qld, Australia
[6] Univ Queensland, Ctr Translat Antiinfect Pharmacodynam, Sch Pharm, Brisbane, Qld, Australia
[7] Univ Ghent, Dept Diagnost Sci, Ghent, Belgium
[8] Ghent Univ Hosp, Dept Lab Med, Ghent, Belgium
[9] Royal Brisbane & Womens Hosp, Dept Intens Care Med, Brisbane, Qld, Australia
[10] CHU Nimes, Dept Anesthesiol & Crit Care, Nimes, France
[11] Royal Brisbane & Womens Hosp, Dept Pharm, Brisbane, Qld, Australia
基金
澳大利亚国家健康与医学研究理事会; 英国医学研究理事会;
关键词
Piperacillin; Pharmacokinetics; Critically ill; Saturation; BETA-LACTAM ANTIBIOTICS; POPULATION PHARMACOKINETIC ANALYSIS; NONLINEAR PHARMACOKINETICS; TAZOBACTAM; PHARMACODYNAMICS; QUANTIFICATION; INTERMITTENT; BOLUS;
D O I
10.1016/j.ijantimicag.2019.08.024
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The study aimed to evaluate saturation of piperacillin elimination in critically ill adult patients. Seventeen critically ill adult patients received continuous and intermittent infusion of piperacillin/tazobactam. Piperacillin plasma concentrations (n = 217) were analysed using population pharmacokinetic (PopPK) modelling. Post-hoc simulations were performed to evaluate the type I error rate associated with the study. Unseen data were used to validate the final model. The mean error (ME) and root mean square error (RMSE) were calculated as a measure of bias and imprecision, respectively. A PopPK model with parallel linear and non-linear elimination best fitted the data. The median and 95% confidence interval (CI) for the model parameters drug clearance (CL), volume of central compartment (V), volume of peripheral compartment (V-p) and intercompartmental clearance (Q) were 9 (7.69-11) L/h, 6.18 (4.93-11.2) L, 11.17 (7.26-12) L and 15.61 (12.66-23.8) L/h, respectively. The Michaelis-Menten constant (K-m) and the maximum elimination rate for Michaelis-Menten elimination (V-max) were estimated without population variability in the model to avoid overfitting and inflation of the type I error rate. The population estimates for K-m and V-max were 37.09 mg/L and 353.57 mg/h, respectively. The bias (ME) was -20.8 (95% CI -26.2 to -15.4) mg/L, whilst imprecision (RMSE) was 49.2 (95% CI 41.2-56) mg/L. In conclusion, piperacillin elimination is (partially) saturable. Moreover, the population estimate for K-m lies within the therapeutic window and therefore saturation of elimination should be accounted for when defining optimum dosing regimens for piperacillin in critically ill patients. (C) 2019 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:741 / 749
页数:9
相关论文
共 50 条
  • [31] Prolonged vs intermittent infusion of piperacillin/tazobactam in critically ill patients: A narrative and systematic review
    Yusuf, Erlangga
    Spapen, Herbert
    Pierard, Denis
    JOURNAL OF CRITICAL CARE, 2014, 29 (06) : 1089 - 1095
  • [32] Outcomes of Extended-Infusion Piperacillin-Tazobactam: A Retrospective Analysis of Critically Ill Patients
    Lee, Grace C.
    Liou, Hansheng
    Yee, Russell
    Quan, Clifford F.
    Neldner, Katherine
    CLINICAL THERAPEUTICS, 2012, 34 (12) : 2297 - 2300
  • [33] In vivo Elimination of Clonidine by Continuous Venovenous Hemofiltration in Critically Ill Patients
    van den Oever, Huub L. A.
    Zeeman, Marieke
    Nassikovker, Polina
    Bles, Carmen
    van Steveninck, Fred A. L.
    de Meijer, Arthur R.
    Kruisdijk-Gerritsen, Arriette
    Arbouw, Maurits
    BLOOD PURIFICATION, 2020, 49 (05) : 622 - 626
  • [34] Transition From Continuous Infusion Fentanyl to Hydromorphone in Critically Ill Patients
    Kovacevic, Mary P.
    Szumita, Paul M.
    Dube, Kevin M.
    DeGrado, Jeremy R.
    JOURNAL OF PHARMACY PRACTICE, 2020, 33 (02) : 129 - 135
  • [35] Continuous infusion of meropenem in critically ill patients: practical considerations Reply
    Chytra, Ivan
    Stepan, Martin
    Benes, Jan
    Pelnar, Petr
    Zidkova, Alexandra
    Bergerova, Tamara
    Pradl, Richard
    Kasal, Eduard
    CRITICAL CARE, 2012, 16 (04):
  • [36] Linezolid Pharmacokinetics in Critically Ill Patients: Continuous Versus Intermittent Infusion
    Hui, Ligia-Ancuta
    Bodolea, Constantin
    Popa, Adina
    Vlase, Ana-Maria
    Hiriscau, Elisabeta Ioana
    Vlase, Laurian
    ANTIBIOTICS-BASEL, 2024, 13 (10):
  • [37] SAFETY OF CONTINUOUS INFUSION OF POLYMYXIN B THERAPY IN CRITICALLY ILL PATIENTS
    Alvarado, Yarelis
    Cruz, Raquel
    Gonzalez, Julia
    Perez, Yeiry
    Wolowich, William
    CRITICAL CARE MEDICINE, 2016, 44 (12)
  • [38] A higher dose of vancomycin in continuous infusion is needed in critically ill patients
    Jeurissen, A.
    Sluyts, I.
    Rutsaert, R.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2011, 37 (01) : 75 - 77
  • [39] Bumetanide continuous-infusion dosing in critically ill pediatric patients
    Bulkley, Christina F.
    Johnson, Peter N.
    Henry, Emilie
    Harrison, Donald
    Lewis, Teresa V.
    Miller, Jamie L.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2012, 69 (17) : 1458 - +
  • [40] CONTINUOUS-INFUSION OF HALOPERIDOL CONTROLS AGITATION IN CRITICALLY ILL PATIENTS
    RIKER, RR
    FRASER, GL
    COX, PM
    CRITICAL CARE MEDICINE, 1994, 22 (03) : 433 - 440